Navigation Links
VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
Date:10/5/2007

econd half of 2007. In addition, VioQuest and the U.S. Army are planning to submit a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) in 2007 for Lenocta(TM) for the treatment of leishmaniasis.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. In addition, this press release also includes forward-looking statements regarding the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of VioQuest's drug development product candidates. These statements are subject to various risks and uncertainties and include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM), VQD-002, and Xyfid(TM) will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 3
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
(Date:11/18/2014)... FL (PRWEB) November 17, 2014 ... point-of-care diagnostic tests – today announces its third ... and Prevention’s (CDC) Get Smart About Antibiotics Week ... Week is a national campaign designed to highlight ... health departments, and non-profit and for-profit partners to ...
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Provider™ solution ... Consummate Provider™ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Viruses can wreak havoc on bacteria as well as humans ... in place, explains Professor John van der Oost, at the ... the bacterial "immune system" could be used to keep industrial ... his team at Wageningen University in the Netherlands have spent ...
... ... statistically significant pain relief at five minutes post-dose using electronic patient diary data ... PITTSBURGH, PA (Vocus) ... outcomes (PRO) solutions and services for global clinical research, today announced that its ...
... immune system senses and tracks down infection in the body ... immune cells manipulate their movement in response to external signals ... functions but also how cancer cells spread through the body ... the Society for General Microbiology,s spring meeting in Edinburgh, Dr ...
Cached Biology Technology:invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 2invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 3How immune cells 'sniff out' bacteria 2
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at Brigham and Women,s Hospital (BWH) have demonstrated ... human platelet function and causes a peak in platelet ... cardiovascular events. These findings are published in PLoS ... disease is still the number one cause of death ...
... article (DOI: 10.1603/IPM10024) in the Journal of Integrated ... species of thrips present in U.S. cotton, their plant host ... biology, and management practices currently available to growers. ... in the United States and constitute one of the most ...
... DC (Sept 9, 2011) -- The blood levels of ... patients will develop heart problems, need dialysis, and die ... issue of the Journal of the American Society ... which patients need early treatment, thereby lowering their health ...
Cached Biology News:Body clock found to regulate platelet function 2Hormone predicts which kidney patients might die early 2